US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

43.79

+0.26000.60%

Post-market: 43.790.00000.00%16:10 EDT

Volume:4K

Turnover:165.34K

Market Cap:32.84M

PE:- -

High:43.87

Open:43.69

Low:43.61

Close:43.53

52wk High:44.89

52wk Low:31.44

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.13

T/O Rate:0.50%

Dividend:0.14

Dividend Rate:0.32%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts

Natera CEO Steven Leonard Chapman Sells USD 526,544 of Common Stock

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Guardant Health price target raised to $200 from $190 at Guggenheim

Will NCCN Names MRD Test Change Adaptive Biotechnologies Stock Narrative

Simply Wall St.

Guardant Health (GH) Receives a Buy from Bernstein

Natera (NTRA) Receives a Buy from Bernstein

Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says

MT Newswires Live

Adaptive Biotechnologies Highlights MRD Testing Role in New Myeloma Cure Definition from International Myeloma Society

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)

Ligand initiated with an Overweight at Barclays

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Natera, Inc. : RBC Raises Target Price to $460 from $350

THOMSON REUTERS

Wainwright sees upside in Ligand after new CAR-T investment in AvenCell

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell

MT Newswires Live

Ligand and Avencell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

THOMSON REUTERS

Ligand Pharmaceuticals Incorporated - Commits up to $6 Mln in Series C Financing

THOMSON REUTERS

Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

Editas slips amid pressure on gene-editing sector after Anthropic update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/HELX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.79,"timestamp":1790971200000,"preClose":43.53,"halted":0,"volume":3777,"hourTrading":{"tag":"盘后","latestPrice":43.79,"preClose":43.79,"latestTime":"16:10 EDT","volume":7,"amount":306.53,"timestamp":1790971805380,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005972892258212681,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Market Closed","change":0.26,"latestTime":"10-02 16:00:00 EDT","open":43.69,"high":43.865,"low":43.605,"amount":165337,"amplitude":0.005973,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":43.53,"sharesOutstanding":650000,"nav":43.859,"aum":32894030.1,"dividendRate":0.003238,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.79,"preClose":43.79,"latestTime":"16:10 EDT","volume":7,"amount":306.53,"timestamp":1790971805380,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.12822514959299489,"impliedVol":0.052,"impliedVolPercentile":0.0359},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.12822514959299489,"shares":750000,"dividePrice":0.1418,"high":43.865,"amplitude":0.005973,"preClose":43.53,"low":43.605,"week52Low":31.44,"pbRate":"--","week52High":44.89,"institutionHeld":0,"latestPrice":43.79,"eps":0,"divideRate":0.003238,"volume":3777,"delay":0,"ttmEps":0,"open":43.69,"prevYearClose":36.3062,"prevWeekClose":44.296,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":44.296,"twentyDayClose":42.3102,"sixtyDayClose":40.4693},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672728212","title":"ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2672728212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672728212?lang=en_us&edition=fundamental","pubTime":"2026-10-03 17:01","pubTimestamp":1791018089,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($ADPT) ), ( ($MRNA) ), ( ($CRWV) ), ( ($NBIS) ) and ( ($JAZZ) ). Here is a breakdown of their recent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/adpt-mrna-crwv-nbis-jazz-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/adpt-mrna-crwv-nbis-jazz-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4551","MRNY","BK4121","BK4585","BK4588","IE00BN0W2T93.GBP","BK4533","BK4139","BK4534","LGHT","BK4007","HELX","LU0320765992.SGD","BK4548","BK4568","BK4532","LU0889565916.HKD","IE00BN0W2W23.USD","LU0154245756.USD","BK4501","GNOM","MRNA","ADPT","LU0823416689.USD","LU0154245673.USD","IE00BN0W2V16.EUR","JAZZ","MRNX","WDNA","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672906742","title":"Natera CEO Steven Leonard Chapman Sells USD 526,544 of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2672906742","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672906742?lang=en_us&edition=fundamental","pubTime":"2026-10-03 09:35","pubTimestamp":1790991346,"startTime":"0","endTime":"0","summary":"Natera CEO Steven Leonard Chapman sells USD 526,544 of common stockNatera CEO and President Steven Leonard Chapman sold 1,273 common shares on Oct. 1, 2026 at USD 413.31.Chapman reported 96,926 Natera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261003:nNDL7bmVKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera CEO Steven Leonard Chapman Sells USD 526,544 of Common Stock","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065731478.USD","LU0106261612.USD","LU0345770993.USD","LU0345770308.USD","NTRA","LU2065170008.USD","LU0012050646.USD","LU0963586101.USD","LU0053671581.USD","LU2065171402.SGD","LU2264538146.SGD","LU1988902786.USD","BK4139","LU1064131342.USD","HELX","LU2065169927.USD","GNOM","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672104768","title":"Adaptive Biotechnologies is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672104768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672104768?lang=en_us&edition=fundamental","pubTime":"2026-10-01 22:20","pubTimestamp":1790864400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672520357","title":"Guardant Health price target raised to $200 from $190 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672520357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672520357?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:37","pubTimestamp":1790858259,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Guardant Health (GH) to $200 from $190 and keeps a Buy rating on the shares. The firm adjusted its mod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","LU0889565916.HKD","LU0109394709.USD","GNOM","GNMX","EKG","BK4551","LFSC","BK4535","FFOX","GH","HELX","BK4588","PTH","LU0320765992.SGD","GDOC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672573956","title":"Will NCCN Names MRD Test Change Adaptive Biotechnologies Stock Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2672573956","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672573956?lang=en_us&edition=fundamental","pubTime":"2026-10-01 10:16","pubTimestamp":1790820997,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies reported that the updated National Comprehensive Cancer Network Multiple Myeloma Guidelines now feature a dedicated MRD testing page that recommends highly sensitive bone marrow MRD assessment using FDA-approved NGS assays, specifically naming its clonoSEQ test and outlining broader use across treatment stages.\nThe guideline shift gives Adaptive Biotechnologies a differentiated reference point in clinical practice, which could support recurring clonoSEQ testing...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/will-nccn-names-mrd-test-change-adaptive-biotechnologies-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/will-nccn-names-mrd-test-change-adaptive-biotechnologies-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","HELX","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670745514","title":"Guardant Health (GH) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670745514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670745514?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:15","pubTimestamp":1790432125,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Guardant Health, with a price target of $210.00. The company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4588","GDOC","BK4551","EKG","PTH","BK4535","GNOM","GNMX","LFSC","LU0109394709.USD","LU0889565916.HKD","GH","LU0320765992.SGD","BK4585","FFOX","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670471989","title":"Natera (NTRA) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670471989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670471989?lang=en_us&edition=fundamental","pubTime":"2026-09-26 20:25","pubTimestamp":1790425523,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Natera, with a price target of $365.00. The company’s shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/natera-ntra-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/natera-ntra-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1988902786.USD","LU2264538146.SGD","GNOM","LU2065169927.USD","LU0345770993.USD","LU0345770308.USD","LU2065171311.SGD","LU2065171402.SGD","LU2324357040.USD","NTRA","LU1064131342.USD","LU0053671581.USD","LU0012050646.USD","HELX","LU0106261612.USD","BK4139","LU2065170008.USD","LU2065731478.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670628425","title":"Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670628425","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670628425?lang=en_us&edition=fundamental","pubTime":"2026-09-25 23:30","pubTimestamp":1790350202,"startTime":"0","endTime":"0","summary":"Natera's (NTRA) Signatera Genome, the new ultra sensitive version of its molecular residual disease test, could emerge as the dominant clinical offering within a few years, RBC Capital Markets said in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2065170008.USD","LU2065171402.SGD","LU2065171311.SGD","LU0106261612.USD","NTRA","LU1988902786.USD","LU0963586101.USD","HELX","LU0345770308.USD","LU0345770993.USD","BK4139","LU0053671581.USD","LU2324357040.USD","LU2264538146.SGD","GNOM","LU2065731478.USD","LU1064131342.USD","LU2065169927.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670447670","title":"Adaptive Biotechnologies Highlights MRD Testing Role in New Myeloma Cure Definition from International Myeloma Society","url":"https://stock-news.laohu8.com/highlight/detail?id=2670447670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670447670?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:03","pubTimestamp":1790337803,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies highlights MRD testing role in new myeloma cure definition from International Myeloma SocietyAdaptive Biotechnologies highlighted a new International Myeloma Society consensus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL7rxcRq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BCDF","IE00B64PRP62.GBP","BK4112","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","ADPT","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","NDAQ","BK4585","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","LU0314104364.USD","HELX","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670449564","title":"Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670449564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670449564?lang=en_us&edition=fundamental","pubTime":"2026-09-25 16:50","pubTimestamp":1790326207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND), Natera (NTRA) and Aveanna Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-natera-ntra-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-natera-ntra-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","LGND","LU1064131342.USD","LU2065171402.SGD","LU0963586101.USD","LU0012050646.USD","BK4007","NTRA","LU2065170008.USD","XBI","LU0106261612.USD","HELX","GNOM","BK4588","LU0345770993.USD","LU0566484027.USD","LU2065171311.SGD","IE0009354923.USD","BK4581","LU1988902786.USD","LU2324357040.USD","LABU","BK4585","BK4539","XLV","LU1559883803.SGD","BK4139","LU2065169927.USD","LU0345770308.USD","LU2065731478.USD","LU2264538146.SGD","AVAH","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670590449","title":"Ligand initiated with an Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2670590449","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670590449?lang=en_us&edition=fundamental","pubTime":"2026-09-25 16:45","pubTimestamp":1790325913,"startTime":"0","endTime":"0","summary":"Barclays analyst Glen Santangelo initiated coverage of Ligand (LGND) with an Overweight rating and $345 price target The firm says Ligand is “diffe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ligand-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ligand-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELX","LU0566484027.USD","BK4007","LGND","IE0009354923.USD","BK4139","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412443","title":"US Research Roundup-Chevron, Exxon Mobil, GoDaddy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412443?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:58","pubTimestamp":1790319529,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddySept 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Chevron, Exxon Mobi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nL4N45H0CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRL","CNK","CVX","NTRA","UGE","PYPL","BNY","CPT","OBK","GXPE","HELX","GEN","CGEM","ANDG","CMCSA","GPOR","KMX","EMR","OKTA","CF","MMM","OILT","XOM","INFQ","AXGN","FSTA","DMRA","AKAM","RSPC","ACAD","META","CDNL","KNF","FUL","UPW","TRUC","LMRI","GRAL","COST","FFBC","P","TRUN","SO","CRK","XLP","ALM","DRI","STZ","GDDY","AEE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412156","title":"Natera, Inc. : RBC Raises Target Price to $460 from $350","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412156?lang=en_us&edition=fundamental","pubTime":"2026-09-25 11:19","pubTimestamp":1790306366,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H007:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTRA","LU2264538146.SGD","BK4139","LU2324357040.USD","LU0053671581.USD","LU0012050646.USD","HELX","LU1988902786.USD","LU2065731478.USD","LU1064131342.USD","LU2065171311.SGD","LU0345770993.USD","LU0106261612.USD","LU0963586101.USD","LU2065170008.USD","LU2065171402.SGD","LU2065169927.USD","GNOM","LU0345770308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669491495","title":"Wainwright sees upside in Ligand after new CAR-T investment in AvenCell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669491495","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669491495?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:10","pubTimestamp":1790262611,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis notes that this morning, Ligand (LGND) announced an up to $47M investment into AvenCell Therapeutics for d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wainwright-sees-upside-in-ligand-after-new-car-t-investment-in-avencell-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wainwright-sees-upside-in-ligand-after-new-car-t-investment-in-avencell-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","LGND","BK4007","IE0009354923.USD","BK4139","HELX","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499070","title":"FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499070","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499070?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"Mizuho's Bradley Bowers thinks the boost will be substantial. He wrote Tuesday that sales doubled in the launch years of other cancer-screening products-like colon cancer stool test Cologuard from the Exact Sciences unit of Abbott, or the colon cancer blood test Shield from Guardant Health.Galleri screens a person's blood sample for bits of DNA showing features typical of cancer cells. It tells you if it has found a general signal of cancer somewhere in your body-\"Cancer Signal Detected\"-and makes its best guess at the kind of tissue where the cancer is hiding.Clinical trials showed Galleri can detect cancers for which there is no standard screen, such as cancer of the ovary or pancreas. Grail's two big clinical trials showed that it rarely tells you that you have cancer when you don't. When you do have cancer, the test finds it on average about 50% of the 60% of the time.That is good performance, compared with other widely used screens, like the mammogram. Grail plans to tell customer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","BK4082","LU1721429402.USD","TMED","BK4585","LU1721429741.USD","BK4196","LU2112291526.USD","LU2237957811.SGD","LU2324357040.USD","GNOM","PJP","LU0320765992.SGD","SG9999002224.SGD","SGXZ41872573.SGD","LU0320765489.SGD","BK4581","IE00B4R5TH58.HKD","LU1061106388.HKD","GNMX","LU0889565916.HKD","LU0882574055.USD","PTH","HELX","SG9999004303.SGD","BK4551","GRAL","LU2089984988.USD","EKG","LABU","IE0002141913.USD","IE00B2B36J28.USD","IHI","LU1670627923.USD","LU1989763690.USD","BK4588","FFOX","LU0868494617.USD","SG9999002232.USD","LU0122379950.USD","SGXZ23171101.USD","BK4568","GH","LU0289739699.SGD","LU0211331839.USD","BK4535","BK4139","LU1691799644.USD","ABT","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669902467","title":"Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669902467","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669902467?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:35","pubTimestamp":1790249721,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals  said Thursday it agreed to provide up to $47 million to AvenCell Therapeutics to support development of its cell therapy programs.Ligand said it will provide up to $41 million in exchange for a mid-single-digit to low-double-digit royalty on worldwide annual net sales of AvenCell's current and future pipeline.The funding will be provided in four tranches, with later payments tied to clinical milestones and other conditions, it added.Ligand said it also committed up to $6 million to AvenCell's Series C financing.AvenCell is developing therapies in a phase 1 trial to treat cancers, Ligand added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LGND","IE0009354923.USD","BK4139","LU0566484027.USD","LU1559883803.SGD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669846230","title":"Ligand and Avencell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669846230","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669846230?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA7SZPQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IE0009354923.USD","LU1559883803.SGD","HELX","LU0566484027.USD","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462584","title":"Ligand Pharmaceuticals Incorporated - Commits up to $6 Mln in Series C Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462584?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA7SZPQL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","HELX","BK4139","IE0009354923.USD","LU1559883803.SGD","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462637","title":"Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462637","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462637?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":"JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4539","CAR","LENZ","BK4585","R","BK4555","BK4588","BK4099","BK4139","BK4007","03160","IE0009354923.USD","BK4022","LU1559883803.SGD","HELX","LU0566484027.USD","LGND","BK4230","BK4604","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669435367","title":"Editas slips amid pressure on gene-editing sector after Anthropic update","url":"https://stock-news.laohu8.com/highlight/detail?id=2669435367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669435367?lang=en_us&edition=fundamental","pubTime":"2026-09-24 02:55","pubTimestamp":1790189712,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a CRISPR like enzyme system. An...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-slips-amid-pressure-on-gene-editing-sector-after-anthropic-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4556","IDNA","SYNB","EDIT","BK4611","LU1861558580.USD","GNMX","CRSP","BK4585","LU1861559042.SGD","WDNA","HELX","ARKG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}